Denali Therapeutics Inc Total Assets
Denali Therapeutics Inc total assets. Based on the latest financial reports, Denali Therapeutics Inc (DNLI) holds total assets worth $1.16 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Denali Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Denali Therapeutics Inc (2015–2025)
Total assets of Denali Therapeutics Inc from 2015 to 2025. This chart illustrates how Denali Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Denali Therapeutics Inc stock quote for real-time trading data and today's change.
Denali Therapeutics Inc - Asset Composition Analysis
Denali Therapeutics Inc Total Assets Breakdown (December 2025)
Denali Therapeutics Inc total assets breakdown as of December 2025. Denali Therapeutics Inc's total assets of $1.16 Billion consist of 78.7% current assets and 21.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.9% |
| Accounts Receivable | $2.18 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Denali Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore DNLI current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Denali Therapeutics Inc's current assets represent 78.7% of total assets in 2025, a decrease from 91.1% in 2015.
- Cash Position: Cash and equivalents constituted 17.9% of total assets in 2025, down from 83.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Denali Therapeutics Inc Competitors by Total Assets
Key competitors of Denali Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Denali Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.37 | 10.27 | 19.46 |
| Quick Ratio | 8.32 | 10.27 | 19.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $663.84 Million | $843.65 Million | $1.00 Billion |
Denali Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Denali Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.13 |
| Latest Market Cap to Assets Ratio | 2.72 |
| Asset Growth Rate (YoY) | -16.7% |
| Total Assets | $1.14 Billion |
| Market Capitalization | $3.11 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Denali Therapeutics Inc's assets at a significant premium (2.72x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Denali Therapeutics Inc's assets decreased by 16.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Denali Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Denali Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.14 Billion | -16.69% |
| 2024-12-31 | $1.37 Billion | +19.09% |
| 2023-12-31 | $1.15 Billion | -20.98% |
| 2022-12-31 | $1.46 Billion | +3.99% |
| 2021-12-31 | $1.40 Billion | -12.47% |
| 2020-12-31 | $1.60 Billion | +189.98% |
| 2019-12-31 | $553.23 Million | -16.43% |
| 2018-12-31 | $661.98 Million | +36.01% |
| 2017-12-31 | $486.72 Million | +79.56% |
| 2016-12-31 | $271.07 Million | +638.94% |
| 2015-12-31 | $36.68 Million | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pr… Read more